Stock Movers

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Anthropic (ANT) filed for an IPO, warning its technology carried existential risks even as it moved a step closer to being the first company focused primarily on developing the most advanced artificial intelligence models to go public.
The company behind Claude expects to begin trading on the Nasdaq Global Select Market under the symbol ANT, a filing Monday with the US Securities and Exchange Commission showed. Anthropic filed confidentially in June for a listing.
- Meta Platforms (META) is seeking to raise as much as $95 billion from selling common and preferred stock, supporting its development in artificial intelligence with one of the largest equity offerings in history.
The company is offering about $35 billion of common and preferred stock, according to a statement Monday. It also plans to raise as much as about $60 billion in an at-the-market share sale program, which allows companies to sell shares in the open market from time to time. The ATM will consist of its planned Class C nonvoting shares.
- Fair Isaac (FICO) shares are down after the financial services company said late Friday it will hold its wholesale mortgage price for the FICO Score through tri-merge resellers at $10 for lenders and brokers enrolled in its Preferred Program.
See omnystudio.com/listener for privacy information.

Anthropic filed for an IPO, moving a step closer to being the first company focused primarily on developing the most advanced artificial intelligence models to go public.
The company behind Claude expects to begin trading on the Nasdaq Global Select Market under the symbol ANT, a filing Monday with the US Securities and Exchange Commission showed.
For instant reaction, Bloomberg's Paul Sweeney and Jess Menton speak with Bloomberg Executive Editor for Global Tech Peter Elstrom and Bloomberg Intelligence Senior Tech Analyst Mandeep Singh.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Verizon (VZ) shares are moving after it reported its strongest third-quarter performance in wireless customer additions in five years, adding a net 406,000 monthly phone lines.
- PagSeguro (PAGS) is among the many Brazil-linked stocks sliding this morning after President Luiz Inácio Lula da Silva won Brazil’s runoff election with 51.8% of the vote, defeating Flávio Bolsonaro who received 48.2%.
- Surgery Partners (SGRY) is moving on news Bon Secours Mercy Health is in late-stage talks to buy a majority stake in Surgery Partners, the Financial Times reported.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Nu Holdings (NU) is sliding along with several other Brazil-related stocks due to the re-election of President Luiz Inácio Lula da Silva.
- Tesla (TSLA) is gaining as Barclays upgrades to overweight from equal-weight, citing M&A opportunity with SpaceX. Analyst Dan Levy also notes improved trajectory in the electric-car maker’s core business and possible Robotaxi inflection
- Fair Isaac (FICO) is dropping after the financial services company said it will hold its wholesale mortgage price for the FICO Score through tri-merge resellers at $10 for lenders and brokers enrolled in its Preferred Program.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Telefonica falls as much as 8.4%, the most in almost a year, after JPMorgan cut the Spanish telco to underweight from neutral and as Brazil-exposed stocks slide following Luiz Inácio Lula da Silva’s surprise runoff election win.
- Galp Energia SGPS SA said talks with Spain’s Moeve to combine their fuel stations and refining operations in Portugal and Spain have ended without an agreement, thwarting plans to create a major player in the Iberian energy market.
- Genmab shares surge as much as 13%, the most since March 2020, after the drugmaker said a late-stage trial of its experimental treatment for ovarian cancer, Rina-S, met its primary and key secondary endpoints.
See omnystudio.com/listener for privacy information.